{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:49:03Z","timestamp":1789076943109,"version":"build-2803163510"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Nilotinib is a second line tyrosine kinase inhibitor to treat patients with chronic myeloid leukemia after imatinib resistance or intolerance. Drug related pulmonary complication is known to be rare. We discuss a case of nilotinib-induced interstitial lung disease presenting with nonspecific interstitial pneumonia on the unilateral lung.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 46-year-old man with chronic-phase chronic myeloid leukemia presented with cough and weight loss for 2\u200amonths. He had been treated with nilotinib for 52\u200amonths.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Computed tomography scan showed right lung dominant consolidations, ground glass opacities and traction bronchiectasis. Bronchoalveolar lavage fluid analysis revealed no evidence of infection or malignancy. Surgical lung biopsy specimen was consistent with fibrosing nonspecific interstitial pneumonia. The patient was diagnosed with nilotinib induced interstitial lung disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Corticosteroid treatment was initiated with prednisolone (50\u200amg daily) and slowly tapered down for 2\u200amonths.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Cough improved after the course of corticosteroid treatment. However, fibrotic lung lesions persisted. Reinitiation of nilotinib resulted in the worsening of lung lesions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>We report a case of irreversible interstitial lung disease that caused by nilotinib. Clinicians should have suspicion of this potential pulmonary complication in patients with respiratory symptoms and abnormal radiologic findings during nilotinib treatment, albeit rarely.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028701","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T14:00:10Z","timestamp":1643378410000},"page":"e28701","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["A case report of nilotinib-induced irreversible interstitial lung disease"],"prefix":"10.1097","volume":"101","author":[{"given":"Jun Yeun","family":"Cho","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ok-Jun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyun","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dohun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Mi","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94","author":"H\u00f6glund","year":"2015","journal-title":"Ann Hematol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00003495-200767020-00010","article-title":"Imatinib","volume":"67","author":"Moen","year":"2007","journal-title":"Drugs"},{"key":"R5-20250504","article-title":"Imatinib-induced irreversible interstitial lung disease: a case report","volume":"98","author":"Zhang","year":"2019","journal-title":"Medicine"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/sj.leu.2404207","article-title":"Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate","volume":"20","author":"Ohnishi","year":"2006","journal-title":"Leukemia"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-07-5015","article-title":"Nilotinib","volume":"14","author":"Deininger","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers"},{"key":"R10-20250504","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026975","article-title":"Pulmonary hypertension in patients with chronic myeloid leukemia","volume":"100","author":"Song","year":"2021","journal-title":"Medicine"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"Le Coutre","year":"2008","journal-title":"Blood"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12185-012-1250-3","article-title":"Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data","volume":"97","author":"Dao","year":"2013","journal-title":"Int J Hematol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/10428194.2011.606940","article-title":"Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib","volume":"53","author":"Delomas","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000079633","article-title":"Interstitial lung disease induced by drugs and radiation","volume":"71","author":"Camus","year":"2004","journal-title":"Respiration"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1874306401206010063","article-title":"Drug induced interstitial lung disease","volume":"6","author":"Schwaiblmair","year":"2012","journal-title":"Open Respir Med J"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0272-5231(03)00138-2","article-title":"Pathologic characteristics of drug-induced lung disease","volume":"25","author":"Flieder","year":"2004","journal-title":"Clin Chest Med"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12185-013-1398-5","article-title":"Nilotinib-induced interstitial lung disease","volume":"98","author":"Go","year":"2013","journal-title":"Int J Hematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:27:01Z","timestamp":1746332821000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028701","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"2021-12-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}